Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SNDX |
---|---|---|
09:32 ET | 30223 | 16.125 |
09:33 ET | 13000 | 16.225 |
09:35 ET | 12373 | 16.195 |
09:37 ET | 70625 | 16.045 |
09:39 ET | 39460 | 16 |
09:42 ET | 21232 | 16.015 |
09:44 ET | 21894 | 16 |
09:46 ET | 31117 | 16 |
09:48 ET | 24541 | 15.965 |
09:50 ET | 12493 | 15.795 |
09:51 ET | 2849 | 15.7 |
09:53 ET | 35348 | 15.7 |
09:55 ET | 35977 | 15.51 |
09:57 ET | 21231 | 15.495 |
10:00 ET | 57714 | 15.31 |
10:02 ET | 43896 | 15.17 |
10:04 ET | 36288 | 15.23 |
10:06 ET | 61321 | 15.13 |
10:08 ET | 34730 | 15.16 |
10:09 ET | 20170 | 15.27 |
10:11 ET | 6989 | 15.33 |
10:13 ET | 5259 | 15.37 |
10:15 ET | 19251 | 15.26 |
10:18 ET | 7344 | 15.31 |
10:20 ET | 19979 | 15.32 |
10:22 ET | 28730 | 15.27 |
10:24 ET | 35295 | 15.08 |
10:26 ET | 8948 | 15.12 |
10:27 ET | 5350 | 15.16 |
10:29 ET | 6600 | 15.12 |
10:31 ET | 9621 | 15.17 |
10:33 ET | 8216 | 15.165 |
10:36 ET | 1464 | 15.24 |
10:38 ET | 6130 | 15.2 |
10:40 ET | 2462 | 15.12 |
10:42 ET | 5705 | 15.17 |
10:44 ET | 4292 | 15.19 |
10:45 ET | 900 | 15.22 |
10:47 ET | 2100 | 15.22 |
10:49 ET | 2200 | 15.14 |
10:51 ET | 1749 | 15.14 |
10:54 ET | 12160 | 15.16 |
10:56 ET | 1489 | 15.2 |
10:58 ET | 2607 | 15.209 |
11:00 ET | 6765 | 15.24 |
11:02 ET | 3247 | 15.25 |
11:03 ET | 3000 | 15.19 |
11:05 ET | 9761 | 15.25 |
11:07 ET | 5179 | 15.24 |
11:09 ET | 118153 | 15.24 |
11:12 ET | 26752 | 15.3001 |
11:14 ET | 10140 | 15.355 |
11:16 ET | 4452 | 15.36 |
11:18 ET | 15906 | 15.36 |
11:20 ET | 4907 | 15.405 |
11:21 ET | 4310 | 15.31 |
11:23 ET | 34384 | 15.46 |
11:25 ET | 14823 | 15.52 |
11:27 ET | 11844 | 15.51 |
11:30 ET | 26421 | 15.46 |
11:32 ET | 2205 | 15.43 |
11:34 ET | 5216 | 15.46 |
11:36 ET | 74682 | 15.655 |
11:38 ET | 3850 | 15.57 |
11:39 ET | 1412 | 15.57 |
11:41 ET | 33480 | 15.58 |
11:43 ET | 1165 | 15.5564 |
11:45 ET | 721 | 15.56 |
11:48 ET | 2900 | 15.54 |
11:50 ET | 850 | 15.5 |
11:52 ET | 1564 | 15.51 |
11:54 ET | 3380 | 15.56 |
11:56 ET | 9130 | 15.62 |
11:57 ET | 10846 | 15.765 |
11:59 ET | 2790 | 15.765 |
12:01 ET | 3143 | 15.8 |
12:03 ET | 20373 | 15.875 |
12:06 ET | 5865 | 15.83 |
12:08 ET | 500 | 15.845 |
12:10 ET | 4095 | 15.885 |
12:12 ET | 200 | 15.89 |
12:14 ET | 2500 | 15.97 |
12:15 ET | 400 | 16.02 |
12:17 ET | 800 | 16.01 |
12:19 ET | 26541 | 16.01 |
12:21 ET | 10643 | 16.02 |
12:24 ET | 56735 | 16.02 |
12:26 ET | 17343 | 16.03 |
12:28 ET | 1100 | 16.035 |
12:30 ET | 1227 | 16.04 |
12:32 ET | 831 | 16.04 |
12:33 ET | 939 | 16.01 |
12:35 ET | 200 | 16.015 |
12:37 ET | 7339 | 16 |
12:39 ET | 889 | 15.995 |
12:42 ET | 5050 | 15.995 |
12:44 ET | 3840 | 16 |
12:46 ET | 9991 | 15.91 |
12:48 ET | 3900 | 15.95 |
12:50 ET | 2272 | 15.91 |
12:51 ET | 1335 | 15.91 |
12:53 ET | 400 | 15.905 |
12:55 ET | 18693 | 16.02 |
12:57 ET | 1495 | 15.995 |
01:00 ET | 2230 | 15.995 |
01:02 ET | 1110 | 15.995 |
01:04 ET | 1678 | 15.99 |
01:06 ET | 1300 | 16 |
01:08 ET | 4488 | 15.89 |
01:09 ET | 3800 | 15.9 |
01:11 ET | 1686 | 15.835 |
01:13 ET | 890 | 15.82 |
01:15 ET | 755 | 15.81 |
01:18 ET | 8374 | 15.82 |
01:20 ET | 300 | 15.81 |
01:22 ET | 900 | 15.81 |
01:24 ET | 24848 | 15.765 |
01:26 ET | 1414 | 15.765 |
01:27 ET | 35088 | 15.83 |
01:29 ET | 3000 | 15.83 |
01:31 ET | 1000 | 15.845 |
01:33 ET | 4279 | 15.8 |
01:36 ET | 1698 | 15.81 |
01:38 ET | 11540 | 15.8017 |
01:40 ET | 4145 | 15.79 |
01:42 ET | 8406 | 15.8 |
01:44 ET | 5000 | 15.825 |
01:45 ET | 11839 | 15.83 |
01:47 ET | 5437 | 15.82 |
01:49 ET | 13934 | 15.835 |
01:51 ET | 6221 | 15.805 |
01:54 ET | 3620 | 15.755 |
01:56 ET | 3275 | 15.72 |
01:58 ET | 4248 | 15.78 |
02:00 ET | 2991 | 15.79 |
02:02 ET | 1525 | 15.8 |
02:03 ET | 3879 | 15.8 |
02:05 ET | 471 | 15.795 |
02:07 ET | 11089 | 15.81 |
02:09 ET | 402 | 15.81 |
02:12 ET | 3887 | 15.775 |
02:14 ET | 1000 | 15.775 |
02:16 ET | 3800 | 15.805 |
02:18 ET | 900 | 15.805 |
02:20 ET | 2328 | 15.8 |
02:21 ET | 2456 | 15.78 |
02:23 ET | 4350 | 15.8 |
02:25 ET | 5260 | 15.805 |
02:27 ET | 5268 | 15.795 |
02:30 ET | 2438 | 15.795 |
02:32 ET | 14910 | 15.855 |
02:34 ET | 2516 | 15.92 |
02:36 ET | 2960 | 15.905 |
02:38 ET | 4344 | 15.84 |
02:39 ET | 21550 | 15.8 |
02:41 ET | 77609 | 15.825 |
02:43 ET | 6015 | 15.81 |
02:45 ET | 20756 | 15.74 |
02:48 ET | 3126 | 15.78 |
02:50 ET | 5235 | 15.765 |
02:52 ET | 1500 | 15.765 |
02:54 ET | 7412 | 15.71 |
02:56 ET | 11662 | 15.625 |
02:57 ET | 7421 | 15.6 |
02:59 ET | 4691 | 15.53 |
03:01 ET | 4045 | 15.52 |
03:03 ET | 7184 | 15.575 |
03:06 ET | 6771 | 15.605 |
03:08 ET | 1700 | 15.64 |
03:10 ET | 2094 | 15.7 |
03:12 ET | 8580 | 15.67 |
03:14 ET | 8187 | 15.64 |
03:15 ET | 1600 | 15.655 |
03:17 ET | 11137 | 15.6 |
03:19 ET | 23218 | 15.6 |
03:21 ET | 14046 | 15.57 |
03:24 ET | 1830 | 15.58 |
03:26 ET | 1200 | 15.575 |
03:28 ET | 12933 | 15.6 |
03:30 ET | 8373 | 15.595 |
03:32 ET | 2901 | 15.605 |
03:33 ET | 71871 | 15.645 |
03:35 ET | 2610 | 15.65 |
03:37 ET | 6413 | 15.6 |
03:39 ET | 11200 | 15.62 |
03:42 ET | 6150 | 15.63 |
03:44 ET | 3239 | 15.62 |
03:46 ET | 2731 | 15.61 |
03:48 ET | 19686 | 15.59 |
03:50 ET | 18448 | 15.51 |
03:51 ET | 713595 | 15.6 |
03:53 ET | 37098 | 15.61 |
03:55 ET | 16192 | 15.615 |
03:57 ET | 29267 | 15.65 |
04:00 ET | 694157 | 15.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Syndax Pharmaceuticals Inc | 1.3B | -4.3x | --- |
Day One Biopharmaceuticals Inc | 1.3B | -13.1x | --- |
ARS Pharmaceuticals Inc | 1.3B | -26.4x | --- |
Praxis Precision Medicines Inc | 1.4B | -7.1x | --- |
Spyre Therapeutics Inc | 1.4B | -3.6x | --- |
Enliven Therapeutics Inc | 1.2B | -13.3x | --- |
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $16.0M |
Shares Outstanding | 85.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.87 |
EPS | $-3.63 |
Book Value | $6.53 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | 83.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,007.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.